IN2014MN02274A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02274A IN2014MN02274A IN2274MUN2014A IN2014MN02274A IN 2014MN02274 A IN2014MN02274 A IN 2014MN02274A IN 2274MUN2014 A IN2274MUN2014 A IN 2274MUN2014A IN 2014MN02274 A IN2014MN02274 A IN 2014MN02274A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- fragments
- therapy
- stroke
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625628P | 2012-04-17 | 2012-04-17 | |
| PCT/US2013/036947 WO2013158748A1 (en) | 2012-04-17 | 2013-04-17 | Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02274A true IN2014MN02274A (de) | 2015-08-07 |
Family
ID=49384031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2274MUN2014 IN2014MN02274A (de) | 2012-04-17 | 2013-04-17 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150104460A1 (de) |
| EP (2) | EP2838562B1 (de) |
| JP (5) | JP6162219B2 (de) |
| CN (2) | CN108285483B (de) |
| BR (1) | BR112014025898A2 (de) |
| CA (1) | CA2870625C (de) |
| ES (2) | ES2870717T3 (de) |
| HK (3) | HK1206997A1 (de) |
| IL (2) | IL235118B (de) |
| IN (1) | IN2014MN02274A (de) |
| MX (1) | MX356347B (de) |
| NZ (1) | NZ701278A (de) |
| WO (1) | WO2013158748A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060099203A1 (en) * | 2004-11-05 | 2006-05-11 | Pease Larry R | B7-DC binding antibody |
| DK3126383T3 (en) * | 2014-04-03 | 2019-04-01 | Igm Biosciences Inc | MODIFIED J-CHAIN |
| WO2016073963A1 (en) * | 2014-11-07 | 2016-05-12 | Mayo Foundation For Medical Education And Research | Treatment of neonatal hypoxia including impairments or effects thereof |
| DK3265575T3 (da) | 2015-03-04 | 2021-05-31 | Igm Biosciences Inc | Cd20-bindende molekyler og anvendelser deraf |
| AU2016329197B2 (en) | 2015-09-30 | 2021-01-21 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| CN113035298B (zh) * | 2021-04-02 | 2023-06-20 | 南京信息工程大学 | 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法 |
| CN113444787A (zh) * | 2021-07-05 | 2021-09-28 | 中山大学附属第七医院(深圳) | 一种自闭症的脂质生物标志物及其应用 |
| CN114276418A (zh) * | 2021-12-28 | 2022-04-05 | 中国科学技术大学 | 一种可用于调控微管、治疗脱髓鞘病变靶向治疗的rna |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| US7473423B2 (en) * | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| BR0015875A (pt) * | 2000-05-10 | 2003-06-24 | Mayo Foundation | Anticorpos igm humano com a capacidade de induzir remielinização, e usos diagnósticos e terapêutico dos mesmos, particularmente no sistema nervoso central |
| PL1648427T3 (pl) | 2003-05-16 | 2014-05-30 | Mayo Found Medical Education & Res | Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgM |
| EP1652925B1 (de) * | 2003-07-15 | 2010-12-08 | Chugai Seiyaku Kabushiki Kaisha | Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm-produktion |
| EP1768999B1 (de) * | 2004-06-30 | 2013-06-19 | Mayo Foundation For Medical Education And Research | Antikörper sHIgM12 zur Behandlung von Multiple-Sklerose |
| WO2006029184A2 (en) * | 2004-09-08 | 2006-03-16 | Expression Diagnostics, Inc. | Genes useful for diagnosing and monitoring inflammation related disorders |
| WO2007109307A2 (en) * | 2006-03-20 | 2007-09-27 | Curagen Corporation | Antibodies directed to angiopoietin-like protein 4 and uses thereof |
| US8796429B2 (en) * | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
| WO2009052374A2 (en) * | 2007-10-18 | 2009-04-23 | Mayo Foundation For Medical Education And Research | Igm-mediated receptor clustering and cell modulation |
| AR071777A1 (es) * | 2008-05-13 | 2010-07-14 | Genentech Inc | Anticuerpos contra receptor tipo inmunoglobulina de leucocitos (anti-pirb), polinucleotidos que codifican dichos anticuerpos y vectores que comprende los polinucleotidos |
| EP3828205A1 (de) * | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1-antikörper |
| CN104725507B (zh) * | 2010-10-19 | 2018-12-21 | 梅奥医学教育和研究基金会 | 用于治疗神经疾病的人抗体及其诊断和治疗用途 |
| WO2016073963A1 (en) * | 2014-11-07 | 2016-05-12 | Mayo Foundation For Medical Education And Research | Treatment of neonatal hypoxia including impairments or effects thereof |
-
2013
- 2013-04-17 ES ES17188389T patent/ES2870717T3/es active Active
- 2013-04-17 CN CN201810021751.XA patent/CN108285483B/zh not_active Expired - Fee Related
- 2013-04-17 CA CA2870625A patent/CA2870625C/en active Active
- 2013-04-17 IN IN2274MUN2014 patent/IN2014MN02274A/en unknown
- 2013-04-17 NZ NZ701278A patent/NZ701278A/en not_active IP Right Cessation
- 2013-04-17 ES ES13778780.0T patent/ES2655077T3/es active Active
- 2013-04-17 EP EP13778780.0A patent/EP2838562B1/de active Active
- 2013-04-17 WO PCT/US2013/036947 patent/WO2013158748A1/en active Application Filing
- 2013-04-17 CN CN201380027368.0A patent/CN104379167B/zh not_active Expired - Fee Related
- 2013-04-17 EP EP17188389.5A patent/EP3305323B1/de active Active
- 2013-04-17 MX MX2014012651A patent/MX356347B/es active IP Right Grant
- 2013-04-17 JP JP2015507147A patent/JP6162219B2/ja not_active Expired - Fee Related
- 2013-04-17 US US14/395,141 patent/US20150104460A1/en not_active Abandoned
- 2013-04-17 BR BR112014025898A patent/BR112014025898A2/pt not_active Application Discontinuation
-
2014
- 2014-10-19 IL IL235118A patent/IL235118B/en active IP Right Grant
-
2015
- 2015-08-11 HK HK15107727.8A patent/HK1206997A1/xx not_active IP Right Cessation
- 2015-08-24 HK HK15108177.1A patent/HK1207565A1/xx not_active IP Right Cessation
-
2017
- 2017-04-28 JP JP2017089783A patent/JP2017127329A/ja not_active Withdrawn
-
2019
- 2019-01-04 JP JP2019000205A patent/JP2019050832A/ja not_active Withdrawn
- 2019-01-17 HK HK19100777.8A patent/HK1258380A1/zh unknown
- 2019-05-15 IL IL266658A patent/IL266658B/en active IP Right Grant
-
2020
- 2020-09-23 JP JP2020158408A patent/JP2021000120A/ja not_active Withdrawn
-
2022
- 2022-05-16 JP JP2022080204A patent/JP2022107016A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014012651A (es) | 2015-05-07 |
| JP2021000120A (ja) | 2021-01-07 |
| HK1207565A1 (en) | 2016-02-05 |
| JP6162219B2 (ja) | 2017-07-12 |
| CN104379167B (zh) | 2018-02-13 |
| EP2838562A1 (de) | 2015-02-25 |
| EP3305323B1 (de) | 2021-02-17 |
| US20150104460A1 (en) | 2015-04-16 |
| IL266658A (en) | 2019-07-31 |
| MX356347B (es) | 2018-05-23 |
| CN108285483B (zh) | 2022-04-26 |
| CA2870625C (en) | 2023-06-20 |
| WO2013158748A1 (en) | 2013-10-24 |
| JP2019050832A (ja) | 2019-04-04 |
| BR112014025898A2 (pt) | 2017-11-07 |
| JP2022107016A (ja) | 2022-07-20 |
| NZ701278A (en) | 2016-12-23 |
| HK1206997A1 (en) | 2016-01-22 |
| ES2655077T3 (es) | 2018-02-16 |
| HK1258380A1 (zh) | 2019-11-08 |
| CN104379167A (zh) | 2015-02-25 |
| JP2015520608A (ja) | 2015-07-23 |
| EP2838562B1 (de) | 2017-08-30 |
| ES2870717T3 (es) | 2021-10-27 |
| IL266658B (en) | 2021-04-29 |
| CA2870625A1 (en) | 2013-10-24 |
| EP3305323A1 (de) | 2018-04-11 |
| JP2017127329A (ja) | 2017-07-27 |
| IL235118A0 (en) | 2014-12-31 |
| EP2838562A4 (de) | 2015-09-30 |
| IL235118B (en) | 2019-06-30 |
| CN108285483A (zh) | 2018-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02274A (de) | ||
| WO2012054077A3 (en) | Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease | |
| CY1121097T1 (el) | Ανθρωπινα αντισωματα κατα toy gfr 3 και μεθοδοι χρησης αυτων | |
| MX2022004300A (es) | Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas. | |
| PH12016501456A1 (en) | Antibody molecules to pd-1 and uses thereof | |
| MY169328A (en) | Compositions for the treatment of dry eye | |
| HK1210968A1 (en) | Compositions and treatment for eye diseases and disorders | |
| MX356800B (es) | Anticuerpo tau humanizado. | |
| WO2013061161A3 (en) | New combination therapies for treating neurological disorders | |
| IL237743A0 (en) | A combination of rasagiline and pridofidine for the treatment of neurodegenerative diseases, and specifically for the treatment of Huntington's disease | |
| BR112018009891A2 (pt) | vesículas extracelulares de célula neural | |
| IN2014DN06792A (de) | ||
| MX2016010953A (es) | Proteinas de fc multimericas. | |
| EA201990403A1 (ru) | Человеческие анти-vegfr-2/kdr-антитела | |
| DK2714888T3 (da) | Rekombinant gær | |
| EA201492102A1 (ru) | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны | |
| IL234882A0 (en) | Preparations containing neurogiulin and their uses for the treatment of peripheral nerve damage | |
| PH12015500663A1 (en) | Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents | |
| MX366046B (es) | Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos. | |
| MX345534B (es) | Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas. | |
| WO2014083432A3 (en) | Female intranasal testosterone gel for treating anorgasmia | |
| MX2013006633A (es) | Beta-hidroxi-gamma-aminofosfonatos para el tratamiento de trastornos inmunes. | |
| TH1601002196A (th) | การใช้โมเลกุลที่ยึดจับเซมาโฟริน-4D สำหรับการบำบัดความผิดปกติของโรคที่มี การทำลายเซลล์ประสาทในสมอง (neurodegenerative disorder) | |
| BR112015032554A2 (pt) | Moduladores do receptor de bradicinina e seu uso | |
| AR083826A1 (es) | Terapia genica para trastornos neurodegenerativos mediante el empleo de un vector del virus adeno-asociado que expresa la proteina de la neurona motora de la supervivencia |